Argos HIV Immunotherapy Offers Potential Reprieve From Antiretrovirals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
HIV patients armed with a new immunotherapy targeted at their personal viral load may be able to take a break from the oppression of antiretroviral therapy or even drop it altogether, if Argos Therapeutics' AGS-004 continues to meet with clinical success